Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

Learn about the flu shot, COVID-19 vaccine, and our masking policy »

Stanford Health Care

EFFICACY OF THE ANTICANCER AGENT CISPLATIN IN THE TREATMENT OF HUMAN CERVICAL SQUAMOUS CARCINOMA XENOGRAFTED IN NUDE-MICE CHEMOTHERAPY PILLAY, C. V., GREENTHOMPSON, R., BROCKUTNE, J. G. 1986; 32 (4): 356-363

Abstract

Two human squamous carcinomas of the cervix, established by serial passage in nude mice, are described. The response of the tumours to cis-diamminedichloroplatinum (CDDP) was assessed by comparing tumour weights and by histological observations. Tumours treated with CDDP 10 mg/kg/week for 2 weeks regressed significantly and microscopy revealed extensive degeneration. Treatment with CDDP 5 mg/kg/week produced tumour growth retardation and microscopy showed some degenerative changes, however, viable cells, many of which were mitotic, were evident. There was, therefore, a dose-response relationship. The sensitivity of the tumours to CDDP lends support to its use in humans with this malignancy.

View details for Web of Science ID A1986D087400007

View details for PubMedID 3731921